Table 5 Baseline characteristics of patients with Non-Diabetes Mellitus
| Â | Â | Unmatched | Propensity score matched | ||||
|---|---|---|---|---|---|---|---|
Characteristic | Cohort (n = 509) | Inpatient Statin (n = 114) | Non Statin (n = 395) | p-value | Inpatient Statin (n = 94) | Non Statin (n = 94) | p-value |
Age, (years) n (%) | |||||||
 Median (IQR) | 65 (52–73) | 67 (57.75–77) | 64 (49–73) | 0.006 | 67 (57–75.5) | 67.5 (59.75–76) | 0.75 |
 18–30 | 23 (4.5) | 0 | 23 (5.8) | 0 | 2 (2.1) | ||
 31–45 | 54 (10.6) | 6 (5.3) | 48 (12.2) | 3 (3.2) | 10 (10.6) | ||
 46–64 | 176 (34.6) | 42 (36.8) | 134 (33.9) | 36 (38.3) | 26 (27.7) | ||
 ≥ 65 | 256 (50.3) | 66 (57.9) | 190 (48.1) | 55 (58.5) | 56 (59.6) | ||
Sex, n (%) | |||||||
 Male | 273 (53.6) | 71 (62.3) | 202 (51.1) | 0.04 | 55 (58.5) | 57 (60.6) | 0.77 |
 Female | 236 (46.4) | 43 (37.7) | 193 (48.9) | 39 (41.5) | 37 (39.4) | ||
Race, n (%) | |||||||
 Blacks | 374 (73.5) | 78 (68.4) | 296 (74.9) | 0.17 | 68 (72.3) | 72 (76.6) | 0.5 |
 Other races | 135 (26.5) | 36 (31.6) | 99 (25.1) | 26 (27.7) | 22 (23.4) | ||
BMI | |||||||
 Median (IQR) | 28.8 (24.9–35.8) | 28 (23.98–34.5) | 29.2 (25.4–36.43) | 0.07 | 29.3 (24.63–34.8) | 26.95 (24.33–32.7) | 0.4 |
 < 18.5 (underweight) | 20 (3.9) | 5 (4.4) | 15 (3.8) | 4 (4.3) | 5 (5.3) | ||
 18.5–24.9 (normal) | 113 (22.2) | 36 (31.6) | 77 (19.5) | 24 (25.5) | 23 (24.5) | ||
 25–29.9 (overweight) | 148 (29.1) | 25 (21.9) | 123 (31.1) | 22 (23.4) | 31 (33) | ||
 ≥ 30 (obese) | 227 (44.6) | 48 (42.1) | 179 (45.3) | 44 (46.8) | 35 (37.2) | ||
Comorbidities, n (%) | |||||||
 Preexisting lung diseases | 172 (33.8) | 41 (36) | 131 (33.2) | 0.58 | 36 (38.3) | 31 (33) | 0.45 |
 Coronary artery disease | 72 (14.1) | 34 (29.8) | 38 (9.6) |  < 0.001 | 26 (27.7) | 22 (23.4) | 0.5 |
 Hypertension | 378 (74.3) | 103 (90.4) | 275 (69.6) |  < 0.001 | 84 (89.4) | 76 (80.9) | 0.1 |
 Hyperlipidemia | 120 (23.6) | 56 (49.1) | 64 (16.2) |  < 0.001 | 38 (40.4) | 37 (39.4) | 0.88 |
 Congestive Heart Failure | 59 (11.6) | 25 (21.9) | 34 (8.6) |  < 0.001 | 20 (21.3) | 21 (22.3) | 0.86 |
 Stroke | 55 (10.8) | 28 (24.6) | 27 (6.8) |  < 0.001 | 18 (19.1) | 20 921.3) | 0.72 |
 Cancer | 53 (10.4) | 7 (6.1) | 46 (11.6) | 0.09 | 7 (7.4) | 4 (4.3) | 0.35 |
 Chronic liver disease | 22 (4.3) | 3 (2.6) | 19 (4.8) | 0.31 | 3 (3.2) | 5 (5.3) | 0.47 |
 Chronic kidney disease | 45 (8.8) | 17 (14.9) | 28 (7.1) | 0.01 | 12 (12.8) | 13 (13.8) | 0.83 |
 ESRD on dialysis | 45 (8.8) | 13 (11.4) | 32 (8.1) | 0.27 | 12 (12.8) | 10 (10.6) | 0.65 |
 Smoking | 211 (41.5) | 55 (48.2) | 156 (39.5) | 0.1 | 43 (45.7) | 48 (51.1) | 0.47 |
 Insurance | |||||||
 Uninsured | 2 (0.4) | 0 | 2 (0.5) | 0.08 | 0 | 1 (1.1) | 0.44 |
 Medicaid | 155 (30.5) | 29 (25.4) | 126 (31.9) | 21 (22.3) | 23 (24.5) | ||
 Medicare | 299 (58.7) | 78 (68.4) | 221 (55.9) | 66 (70.2) | 67 (71.3) | ||
 Private | 53 (10.4) | 7 (6.1) | 46 (11.6) | 7 (7.4) | 3 (3.2) | ||
Days from symptom onset to hospital presentation | |||||||
 0–5 | 360 (70.7) | 90 (78.9) | 270 (68.4) | 0.06 | 77 (81.9) | 66 (70.2) | 0.25 |
 6–10 | 88 (17.3) | 11 (9.6) | 77 (19.5) | 9 (9.6) | 18 (19.1) | ||
 11–15 | 30 (5.9) | 5 (4.4) | 25 (6.3) | 5 (5.3) | 6 (6.4) | ||
 16 +  | 10 (2) | 3 (2.6) | 7 (1.8) | 3 (3.2) | 4 (4.3) | ||
CURB-65 at presentation | |||||||
 0 | 145 (28.5) | 18 (15.8) | 127 (32.2) | 0.004 | 14 (14.9) | 21 (22.3) | 0.17 |
 1 | 157 (30.8) | 43 (37.7) | 114 (28.9) | 36 (38.3) | 27 (28.7) | ||
 2 | 129 (25.3) | 30 (26.3) | 99 (25.1) | 27 (28.7) | 30 (31.9) | ||
 3 | 57 (11.2) | 20 (17.5) | 37 (9.4) | 15 (16) | 11 (11.7) | ||
 4 | 12 (2.4) | 1 (0.9) | 11 (2.8) | 0 | 4 (4.3) | ||
 5 | 7 (1.4) | 2 (1.8) | 5 (1.3) | 2 (2.1) | 1 (1.1) | ||